Tuberkulóza a respirační nemoci
- Address
- lock Available on a paid plan
Tuberkulóza a respirační nemoci
This respiratory medicine center specializes in clinical research focused on chronic pulmonary conditions, with particular expertise in evaluating novel therapeutic combinations for chronic obstructive pulmonary disease (COPD). The center is actively engaged in advanced pharmaceutical trials examining innovative treatment strategies designed to optimize lung function and improve patient outcomes.
- Comparative efficacy studies of fixed-dose combination therapies for COPD management
- Advanced pulmonary function assessment and FEV1 measurement protocols
- Safety and tolerability evaluation of respiratory medications
The center's research infrastructure supports sophisticated pre-dose lung function testing and comprehensive monitoring of treatment responses in patients with chronic respiratory diseases. Their clinical trial portfolio demonstrates a commitment to advancing therapeutic options through rigorous comparative effectiveness research in respiratory medicine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tuberkulóza a respirační nemoci
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Beclometasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide in COPD: A Randomized, Double-Blind Study | Chiesi Farmaceutici S.p.A. | Phase III | Not Recruiting | Apr 2022 | Dec 2025 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 1 | Unknown | 2022-04-22 | 2022-04-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.